Skip to main content

Table 1 Schedule of data collection

From: Design paper: A phase II study of Bevacizumab and Erlotinib in patients with non-Squamous non-small cell lung cancer that is refractory or relapsed after 1-2 previous Treatment (BEST)

  Baseline Under
treatment
At termination
of treatment
After termination
of treatment
Physical examination     
   Height    
   Weight, performance status  
   Blood pressure
Laboratory test     
   Blood count   
   Biochemistry test   
   Urine test   
   SpO2   *1
   Electrocardiography *1   
   EGFR gene    
Radiology test     
   Chest Xp *1   *1
   Chest CT *2   *3
   Abdominal CT/Ultra sonography *2   *3
   Head CT/MRI *1   *1
   Bone scintigraphy/PET *1   *1
  1. *1 If necessary
  2. *2 Every 6 weeks
  3. *3 Six weeks after termination if treatment is terminated for reasons other than progression of disease